Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
Healthcare
$3.77 +1.53%
+$0.10 today
- Market cap
- $1.22B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
52W Low $2.25High $7.30
Volume 2.17M
Average 2.73M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$93.09M
FY 2025 · Annual
Investing Cash Flow
-$604,000.00
FY 2025 · Annual
Financing Cash Flow
$274.59M
FY 2025 · Annual
+258.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Depreciation & Amortization | 492K | 1.17M | 1.37M | 1.25M | 1.15M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 18.18M | 18.04M | 7.91M | 13.1M | 13.3M |
| Change in Working Capital | 28.67M | 18.52M | (18.01M) | (12.47M) | (5.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 14.49M | (7.8M) | (2.3M) | (2.92M) | (153K) |
| Other Working Capital | 14.17M | 26.32M | (15.72M) | (9.55M) | (5.22M) |
| Other Non-Cash Items | 10.14M | 39.89M | 47.28M | 6.19M | 6.83M |
| Operating Cash Flow | (117.04M) | (88.39M) | (73.02M) | (81.23M) | (93.09M) |
| Capital Expenditures | (21.55M) | (24.87M) | (7.37M) | (374K) | (738K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (6.25M) | (61K) | (3.48M) | 11K | 134K |
| Investing Cash Flow | (21.55M) | (24.93M) | (7.35M) | (363K) | (604K) |
| Debt Repayment | 39.96M | 0 | (3.45M) | 0 | 9.24M |
| Common Stock Issued | (360K) | 53.24M | 140.79M | 76.78M | 265.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (514K) | (1.15M) | (947K) | (96K) | (337K) |
| Financing Cash Flow | 39.08M | 52.1M | 136.39M | 76.68M | 274.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (99.51M) | (61.22M) | 56.02M | (4.9M) | 180.9M |
| Free Cash Flow | (138.6M) | (113.26M) | (80.39M) | (81.6M) | (93.83M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$109.0M
+ D&A$1.1M
+ Stock-Based Comp$13.3M
+ Deferred Tax$0
- Working Capital-$5.4M
+ Other Non-Cash$6.8M
= Operating Cash Flow-$93.1M
- Capex-$738.0K
= Free Cash Flow-$93.8M
Analysis
FY2025 free cash flow is -$93.8M. FCF conversion is 86.1% of net income. Operating cash flow was -$93.1M, with capex of -$738.0K. The largest bridge item is Stock-Based Comp at $13.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 |
Does TSHA generate free cash flow?
Taysha Gene Therapies, Inc. (TSHA) generated -$93.83M of free cash flow in fiscal 2025.
How much operating cash flow does TSHA produce?
Operating cash flow was -$93.09M, before capital expenditures of $738,000.00.
Continue the stock analysis
Jump to another research area for this company.